<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994030</url>
  </required_header>
  <id_info>
    <org_study_id>BDMD 6-2018</org_study_id>
    <nct_id>NCT02994030</nct_id>
  </id_info>
  <brief_title>Biomarker for Duchenne Muscular Dystrophy</brief_title>
  <acronym>BioDuchenne</acronym>
  <official_title>Biomarker for Duchenne Muscular Dystrophy: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify biomarker/s for
      Duchenne Muscular Dystropy (DMD) and to explore the clinical robustness, specificity, and
      long-term variability of these biomarker/s.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne Muscular Dystrophy (DMD) is a devastating inherited neuromuscular disorder that
      affects 1 in 3300 live male births (females can be mildly affected carriers). DMD causes
      progressive weakness and loss of muscle mass, with symptoms usually appearing in early
      childhood. DMD arises from mutations in the DMD gene that codes for dystrophin.

      The DMD gene is located on the short arm of chromosome X (locus Xp21) and codes for
      dystrophin, containing 3685 amino acid residues. 60-65% of DMD mutations are large
      dele-tions, 10-30% are nonsense and frame-shift mutations, 5-15% are duplications, and 2% are
      intronic or 5`- and 3`-UTR alterations.Dystrophin aggregates as a homotetramer in the
      skeletal muscles or associates with actin and Dystrophin-Associated Glycoproteins (DAGs),
      forming a stable complex that interacts with laminin in the extracellular matrix. Dystrophin
      is considered a key structural element in the muscle fiber, whose primary function is to
      stabilize plasma mem-brane, while the DAGs maintain the sarcolemmal stability by mediating
      the complex interactions of the muscle membrane and extracellular environment. The low levels
      of dystrophin lead to cellular instability and progressive leakage of intracellular
      components, explaining the characteristically high levels of creatine phosphokinase (CPK) in
      the blood of DMD patients.

      Biomarkers serve as measurable indicators of normal biological or pathological processes.
      They are typically directly linked to genetic variants in specific genes and can predict,
      diagnose, monitor, and assess the severity of a disease. It is the goal of this study to
      identify, validate, and monitor biochemical markers from DMD affected participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of DMD biomarker/s</measure>
    <time_frame>36 weeks</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of DMD biomarker/s</measure>
    <time_frame>36 months</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Increased Lordosis/Scoliosis</condition>
  <condition>Hyporeflexia</condition>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Red-Green Color Blindness</condition>
  <condition>Lordosis</condition>
  <condition>Scoliosis</condition>
  <condition>Muscular Atrophy</condition>
  <condition>Muscular Weakness</condition>
  <arm_group>
    <arm_group_label>Participants with Duchenne Muscular Dystrophy (DMD)</arm_group_label>
    <description>Participants diagnosed with Duchenne Muscular Dystrophy (DMD) aged between 2 months and 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (Centocard®)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Duchenne Muscular Dystrophy (DMD)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Informed consent is obtained from the parent/ legal guardian

          -  The participant is aged between 2 months and 50 years

          -  The diagnosis of DMD is genetically confirmed by CENTOGENE

        EXCLUSION CRITERIA

          -  Informed consent is not obtained from the parent/ legal guardian.

          -  The participant is younger than 2 months or older than 50 years

          -  The diagnosis of DMD is not genetically confirmed by CENTOGENE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centogene AG Rostock</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Volha Skrahina, PhD</last_name>
    <phone>+4938180113594</phone>
    <email>volha.skrahina@centogene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elkomi</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University-Medical Genetics</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <phone>+20 (0)1060260052</phone>
      <email>elsayed683@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omnia El Rashidy, MD</last_name>
      <phone>+20 (0)0224512900</phone>
      <email>omniarashidy@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Omnia El Rashidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams Univirsity</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoda Tomoum, MD</last_name>
      <phone>+20 (0)0224156526</phone>
      <email>hodatomoum@gmail.com</email>
    </contact>
    <contact_backup>
      <email>mennahshata@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hoda Tomoum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences &amp; Research Centre</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 (0)4842851234</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navi Mumbai Institute of Research In Mental And Neurological Handicap (NIRMAN)</name>
      <address>
        <city>Mumbai</city>
        <zip>400705</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Jalan, MD</last_name>
      <phone>+91 (0)2267910237</phone>
      <email>jalananil12@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Anil Jalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American of science and technology</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre Megarbane, MD</last_name>
      <phone>+33 (0)610403851</phone>
      <email>andre.megarbane@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Andre Megarbane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's hospital, Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>O8406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <phone>+37 (0)063009244</phone>
      <email>rimante.cerkauskiene@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital for Children &quot;Louis Turcanu&quot;</name>
      <address>
        <city>Timişoara</city>
        <zip>682041</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Chirita, MD</last_name>
      <phone>+40 (0)732890217</phone>
      <email>adela.chirita@umft.ro</email>
    </contact>
    <investigator>
      <last_name>Adela Chirita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo 8</city>
        <zip>300011</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eresha Jasinge, MD</last_name>
      <phone>+94 (0)712793328</phone>
      <email>eresha.jasinge@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eresha Jasinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Hospital for psychiatrie and Neurology</name>
      <address>
        <city>Abu Dhabi</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dina Saleh, MD</last_name>
      <email>d.saleh@americancenteruae.com</email>
    </contact>
    <investigator>
      <last_name>Dina Saleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dubai Hospital</name>
      <address>
        <city>Dubai</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hayat Khan, MD</last_name>
      <phone>+97 (0)10569264939</phone>
      <email>hayatkhan321@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Hayat Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>India</country>
    <country>Lebanon</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>Sri Lanka</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://centogene.com</url>
    <description>Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 22, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne Disease</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Lordosis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Color Vision Defects</mesh_term>
    <mesh_term>Reflex, Abnormal</mesh_term>
    <mesh_term>Swayback</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

